Neuronetics stock leans on its core therapy platform.

By Christina Vaughn, Background & Management desk. Reviewed on July 3, 2026 at 5:49 p.m. ET.

Neuronetics Inc (US63009R1005) remains a Nasdaq-listed medical-device company focused on treating depression with its NeuroStar platform. The stock gives investors direct exposure to a therapy-driven commercial model, with the US market still the key reference point for trading and coverage.

Business model first

Neuronetics' core product is NeuroStar Advanced Therapy, a noninvasive treatment system used in mental health care settings. The company describes its platform as a clinic-based offering built around patient access, physician adoption, and recurring utilization.

Trading context

The shares trade on Nasdaq under STIM, which keeps the story anchored in the US small-cap healthcare universe. For investors, the company's execution on commercial adoption remains the central variable.

NeuroStar therapy

NeuroStar Advanced Therapy is the product at the center of the business, and it is the main commercial driver behind Neuronetics' revenue base. The system is aimed at outpatient treatment settings and is marketed as a non-systemic option in mental health care.

Price check

Neuronetics shares were not accompanied by a verified live quote in the available search results. The stock is listed on Nasdaq, and the latest confirmed company context remains the best available anchor for readers today.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.